公开(公告)号：US12025610B2

公开(公告)日：2024-07-02

申请号：US17234448

申请日：2021-04-19

Applicant: Quest Diagnostics Investments LLC

Inventor： Dov Shiffman ,  Carmen Tong ,  James J. Devlin ,  Michael J. McPhaul

IPC: G01N33/49 ,  G01N30/72 ,  G01N33/68 ,  G01N33/74

CPC classification number: G01N33/492 ,  G01N30/7266 ,  G01N33/6848 ,  G01N33/74 ,  G01N2333/62 ,  G01N2800/042 ,  G01N2800/50

Abstract: Methods are described for diagnosing or prognosing insulin resistance in diabetic and pre-diabetic patients, the method comprising determining the amount of insulin and C-peptide in a sample. Provided herein are mass spectrometric methods for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.

公开(公告)号：US20240133865A1

公开(公告)日：2024-04-25

申请号：US18323844

申请日：2023-05-24

Applicant: Laboratory Corporation of America Holdings

Inventor： Ute Geigenmuller ,  Doris Damian ,  Maciej Pacula ,  Mark A. DePristo ,  Jeffrey R. Luber

IPC: G01N33/49 ,  G01N33/68 ,  G16H50/20 ,  G16H50/30 ,  G16Z99/00

CPC classification number: G01N33/492 ,  G01N33/6896 ,  G16H50/20 ,  G16H50/30 ,  G16Z99/00 ,  G01N2800/28 ,  G01N2800/38

Abstract: In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.

公开(公告)号：US20240019417A1

公开(公告)日：2024-01-18

申请号：US18313182

申请日：2023-05-05

Applicant: Laboratory Corporation of America Holdings

Inventor： Ute Geigenmuller ,  Doris Damian ,  Maciej Pacula ,  Mark A. DePristo

IPC: G01N33/49 ,  G01N33/50 ,  G01N33/68 ,  G01N33/70 ,  G01N33/82

CPC classification number: G01N33/492 ,  G01N33/50 ,  G01N33/6896 ,  G01N33/70 ,  G01N33/82 ,  G01N2560/00 ,  G01N2570/00 ,  G01N2800/28 ,  G01N2800/2814

Abstract: In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.

公开(公告)号：US20230398545A1

公开(公告)日：2023-12-14

申请号：US18234317

申请日：2023-08-15

Applicant: Essenlix Corporation

Inventor： Stephen Y. CHOU ,  Wei DING ,  Ji Qi ,  Yufan Zhang

IPC: B01L3/00 ,  G01N1/28 ,  G01N33/49

CPC classification number: B01L3/5088 ,  G01N1/2813 ,  G01N33/492 ,  B01L2200/022 ,  B01L2200/025 ,  B01L2300/0636 ,  B01L2300/0816 ,  B01L2300/0829 ,  B01L2300/0851 ,  B01L2300/0887 ,  B01L2300/123 ,  B01L2400/0481

Abstract: One aspect of the present invention is to provide the device and methods for performing an assay that uses the multiplexing of sample thicknesses on the same plate. The sample thickness multiplexing can offer many information that is unavailable in using a single sample thickness.

公开(公告)号：US11806717B2

公开(公告)日：2023-11-07

申请号：US17268685

申请日：2019-08-16

Applicant: Essenlix Corporation

Inventor： Stephen Y. Chou ,  Wei Ding ,  Ji Qi ,  Yufan Zhang

IPC: B01L3/00 ,  G01N1/28 ,  G01N33/49

CPC classification number: B01L3/5088 ,  G01N1/2813 ,  G01N33/492 ,  B01L2200/022 ,  B01L2200/025 ,  B01L2300/0636 ,  B01L2300/0816 ,  B01L2300/0829 ,  B01L2300/0851 ,  B01L2300/0887 ,  B01L2300/123 ,  B01L2400/0481

Abstract: One aspect of the present invention is to provide the device and methods for performing an assay that uses the multiplexing of sample thicknesses on the same plate. The sample thickness multiplexing can offer many information that are unavailable in using a single sample thickness.

公开(公告)号：US11674903B2

公开(公告)日：2023-06-13

申请号：US15305940

申请日：2015-04-23

Applicant: John L. Robertson ,  Ryan Senger ,  Pang Du

Inventor： John L. Robertson ,  Ryan Senger ,  Pang Du

IPC: G01N21/65 ,  A61M1/16 ,  A61B5/00 ,  G16H10/40 ,  G16H20/40 ,  G01N33/49 ,  A61M1/36 ,  A61B5/145 ,  A61M1/14 ,  A61M1/28

CPC classification number: G01N21/65 ,  A61B5/0075 ,  A61B5/14525 ,  A61B5/6866 ,  A61M1/14 ,  A61M1/1609 ,  A61M1/1619 ,  A61M1/1692 ,  A61M1/282 ,  A61M1/3609 ,  G01N33/492 ,  G16H10/40 ,  G16H20/40 ,  A61M2205/3313 ,  A61M2205/50 ,  A61M2205/52 ,  G01N21/658 ,  G01N2570/00

Abstract: A system and method for monitoring the health of dialysis patients with Raman spectroscopy measurements of one or more target analytes is described. The methods include irradiating one or more fluids of interest with light to produce one or more spectrum and detecting the spectrum with a detector. The fluids of interest are preferably those related to dialysis, including hemodialysis and peritoneal dialysis. In a preferred embodiment, the fluids are irradiated with monochromatic light, and one or more Raman spectra are detected as a result of the irradiation. The fluids may be irradiated within the dialysis tubing itself, or removed from the dialysis tubing and irradiated in a separate chamber. The Raman spectra of one or more target analytes of a dialysis patient may be followed over time or compared to one or more reference spectra, thereby providing information on the health of dialysis patients.

公开(公告)号：US20230168240A1

公开(公告)日：2023-06-01

申请号：US18072496

申请日：2022-11-30

Applicant: Trividia Health, Inc.

Inventor： Brent E. Modzelewski ,  Steven V. Leone

IPC: G01N33/49 ,  B01L3/00

CPC classification number: G01N33/492 ,  B01L3/502715 ,  B01L2300/0645 ,  B01L2300/0825

Abstract: The present disclosure provides systems and methods for measuring a property of a sample. In some embodiments, the system comprises a test strip for collecting the sample, and a diagnostic measuring device configured to receive the test strip and measure a concentration of an analyte in the sample received on the test strip. The diagnostic measuring device further comprises a processor programmed to execute an analyte correction for correcting a measurement of the sample due to one or more interferents, including hematocrit, by using a four-wire sense circuit to measure HCT true complex impedance. The complex HCT impedance is mapped to HCT percentage by empirical methods and can then be used to compensate the glucose measurement for a more accurate blood glucose result.

公开(公告)号：US20230145119A1

公开(公告)日：2023-05-11

申请号：US17967523

申请日：2022-10-17

Applicant: ABBOTT DIABETES CARE INC.

Inventor： Michael R. Love ,  Michael J. Fullmer ,  Kurt E. Leno ,  Xuandong Hua ,  Mark Sloan ,  Lei He ,  Glenn Berman

IPC: G01N33/49 ,  A61B5/00 ,  A61B5/145 ,  H04W4/80 ,  H04W4/38 ,  H04W12/02

CPC classification number: G01N33/492 ,  A61B5/0026 ,  A61B5/14532 ,  H04W4/80 ,  H04W4/38 ,  H04W12/02 ,  A61B5/0022 ,  A61B5/1451 ,  A61B5/14546 ,  A61B5/6802 ,  A61B5/6898 ,  A61B5/14507 ,  A61B5/1112

Abstract: Systems, devices and methods are provided that allow for enhanced performance, power efficiency, interoperability, data security and user privacy for in vivo analyte monitoring systems that utilize wireless communications. The in vivo analyte monitoring systems can include a Bluetooth or Bluetooth Low Energy enabled handheld relay device for wirelessly relaying analyte data between a sensor unit device and one or more reader devices. The in vivo analyte monitoring systems can employ advertisement and encryption schemes for wirelessly transmitting data in a manner that allows for improved security, efficiency and privacy.

公开(公告)号：US20190242872A1

公开(公告)日：2019-08-08

申请号：US16369242

申请日：2019-03-29

Applicant: Bruce Yacyshyn ,  Mary E. Yacyshyn

Inventor： Bruce Yacyshyn ,  Mary E. Yacyshyn

IPC: G01N33/49 ,  A61K31/606 ,  A61K31/196

CPC classification number: G01N33/492 ,  A61K31/196 ,  A61K31/606 ,  G01N2800/065 ,  G01N2800/52 ,  Y02A50/409

Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified target biomarkers associated with gender differential responses to mesalamine, and includes one or more panels of target biomarkers that distinguishes mesalamine response differences between genders and determines the efficacy of mesalamine for patients being treated for various UC conditions and effectively identifies and validates novel drug targets for new UC therapeutics, new diagnostics and diagnostics standards for UC therapeutic strategies.

公开(公告)号：US20180321267A1

公开(公告)日：2018-11-08

申请号：US15772834

申请日：2016-11-03

Applicant: Metabolon, Inc.

Inventor： Adam D. Kennedy ,  Matthew W. Mitchell ,  Meredith V. Brown ,  Kay A. Lawton ,  Shaun Lonergan ,  Jacob Wulff

IPC: G01N35/00 ,  G06F19/28 ,  G01N33/49

CPC classification number: G01N35/00613 ,  G01N33/48 ,  G01N33/492 ,  G01N33/50 ,  G01N33/5308 ,  G01N33/66 ,  G01N33/68 ,  G01N33/92 ,  G01N2560/00 ,  G01N2570/00 ,  G06F19/10 ,  G06F19/28

Abstract: A method of assessing the quality of a biological sample while maintaining the viability of the biological sample for intended use analysis is described herein. The method includes analyzing a biological sample obtained from a subject for an intended use, assessing the quality of the biological sample using one or more biomarkers of sample quality, and simultaneously performing intended use analysis on the same sample. Assessing the quality of the sample can include assessing compliance with sample handling protocols and assessing subject compliance.